Pathogenic effects of maternal antinuclear antibodies during pregnancy in women with lupus

Rafael Herrera-Esparza, Juan José Bolain-y-Goytia, Esperanza Avalos-Díaz
Department of Immunology, UACB - Universidad Autónoma de Zacatecas, México

Abstract

Lupus is an autoimmune disease that primarily affects young women of childbearing age. Fertility rates in lupus patients depend on various factors, including disease activity, nephritis, and the presence of antiphospholipid antibodies; however, after lupus patients become pregnant, different factors may affect the course of pregnancy, such as the production of autoantibodies, pre-existing renal disease, and eclampsia, among others. The placenta is a temporary membrochorial organ that prevents immunological conflict due to exposure to alloantigens at the maternal-fetal interface; placental regulatory T cells play a major role in maternal-fetal tolerance. Typically, significant amounts of maternal IgG class antibodies cross the placenta and enter the fetal circulation. This transition depends on the distribution of Fe receptors along the syncytiotrophoblast. The production of antinuclear antibodies (ANA) is a hallmark of lupus, and these autoantibodies can form immune complexes that are typically trapped in the placenta during gestation. However, the entry of ANA into the fetal circulation depends on the IgG-ANA concentration and the FcR placental density. Maternal antinuclear antibodies with anti-Ro or anti-La specificity might be pathogenic to the fetus if transfused by the placental pathway and could induce neonatal pathologies, such as neonatal lupus and congenital heart block. Here, we review the experimental and clinical data supporting a pathogenic role for such factors and the breakdown of immunological tolerance facilitate disease expression. Lupus primarily affects women of childbearing age, and studies of fertility rates in lupus patients have yielded conflicting results. Cyclophosphamide therapy, anti-phospholipid antibody and/or anti-β-2-microglobulin production, and pre-existing lupus nephritis have been associated with decreased fertility. The prevalence of pre-eclampsia during pregnancy may be higher in lupus patients, and high blood pressure, pre-existing nephritis, and the presence of anti-phospholipid antibodies may worsen the prognosis for a healthy pregnancy.

Introduction

Although Malcolm Hargraves defined lupus erythematosus (LE) factor in 1948, the specific autoantibodies and autoreactive lymphocytes in systemic lupus erythematosus (SLE) patients were not described for two decades. The discovery of these molecules indicated the autoimmune nature of this disease. The prevalence of SLE is approximately 20-150 cases per 100,000 individuals, and the clinical manifestations of this disease result from the failure of immune tolerance mechanisms, resulting in autoimmunity and tissue damage and leading to internal organ dysfunction. The complex pathophysiological mechanisms of SLE include predisposing MHC genes, epigenetic factors that modulate the transcription of cytokines involved in tissue damage, environmental factors such as UV light, or infectious agents. Sexual hormones, including estrogens or pro lactins, are also important, and SLE primarily affects young women. Taken together, these factors and the breakdown of immunological tolerance facilitate disease expression. Placental regulatory T cells play a major role in maternal-fetal tolerance. Typically, significant amounts of maternal IgG class antibodies cross the placenta and enter the fetal circulation. This transition depends on the distribution of Fe receptors along the syncytiotrophoblast. The production of antinuclear antibodies (ANA) is a hallmark of lupus, and these autoantibodies can form immune complexes that are typically trapped in the placenta during gestation. However, the entry of ANA into the fetal circulation depends on the IgG-ANA concentration and the FcR placental density. Maternal antinuclear antibodies with anti-Ro or anti-La specificity might be pathogenic to the fetus if transfused by the placental pathway and could induce neonatal pathologies, such as neonatal lupus and congenital heart block. Here, we review the experimental and clinical data supporting a pathogenic role for maternal autoantibodies transmitted to the fetus.

Placenta

The placenta is a temporary hemochorial organ that penetrates the endometrium and develops upon implantation of the blastocyst and is removed at birth. Placental circulatory systems include i) the umbilical cord, ii) the systemic circulatory system and iii) the yolk system. The expression of Hox genes in the allantoic layer is necessary for the functional development of the placenta; these genes are essential for extra-embryonic placental function and embryo survival. For example, the intervention of Hox is critical for expansion of the placental vasculature. In addition to the vasculature, the placenta is composed of trophoblastic cells derived from the ectoderm, cells originating from the inner cell mass and epiblast (amnion), and minor cell components from the maternal blood. The amnion is an epithelial cell layer that lies on the surface of the basement membrane, and the chorion is juxtaposed to connective tissue associated with chorionic villi and fetal vessels, which are interdigitated with the chorionic decidual and maternal vessels. The placental villous parenchyma comprises 30 to 60 villi, the functional units that facilitate the diffusion and active transport of nutrients and remove metabolic and cellular wastes from the fetal circulation. On the maternal side, the parenchymal villi consist of a thin basal layer corresponding to the maternal-fetal interface that comprises trophoblast and fibrinooid materials, endometrial stromal fibroblast-like cells, macrophages, arteries, and veins. The umbilical cord and chorion tissue originate from the mesoderm, and the cord is derived from the amniotic epithelium and two arteries and one vein embedded in the Wharton gelatin.

Tolerance and placenta

The placenta has evolved protective mechanisms to tolerate the maternal immune system and prevent immunological conflict through constant exposure to alloantigens. Placental regulatory T cells (Tregs) play a major role in tolerance at the maternal-fetal interface. Tregs belong to a CD4+ T cell subset that express the Foxp3 transcription factor; indeed, the congenital or acquired deficiency of Foxp3 results in autoimmunity. There are two pathways for Treg differentiation: the thymic pathway (Treg) and the peripheral pathway (pTreg). In placental mammals, the expression of Foxp3 outside the thymus depends on the CNS1 enhancer, which binds Smad3 and RAR (retinoic acid receptor) and induces TGF-β-dependent Foxp3 expression. CNS1 is a retrotransposon belonging to the SINE MIR
family of retrotransposons. These transposable elements appeared evolutionarily in the Mesozoic era, and CNS1 was amplified in a radiated manner in placental mammals, marsupials, and monotremes.11 CNS1 deficiency in pregnant mice increases fetal resorption, suggesting that during evolution, the CNS1 sequence was generated as a mechanism to strengthen maternal-fetal tolerance.9

Physiological transit of maternal immunoglobulin G

The placental transfer of maternal IgG to the fetus is a physiological fetal protection mechanism that extends through the newborn stage. This protective mechanism is important because the adaptive immune system of the newborn is not exposed to environmental antigens before birth. Among the maternal immunoglobulins, IgG is a unique antibody class that crosses the placenta in significant amounts, and the physiological transit of maternal IgG into the fetus depends on Fc receptor expression in the syncytiotrophoblast (FcγRI, FcγRII, FcγRIIa, FcγRIIIb, and FcRn). For example, in the full-term placenta, FcγRI and FcγRII receptors are predominantly expressed on endothelial and Hofbauer cells, whereas FcγRIIa, FcγRIIib, and FcRn are widely distributed along trophoblasts;12 thus, the passive transfer of maternal antibodies depends on the IgG level and the isotype/FcR ratio. Other miscellaneous factors, such as the integrity of the placenta as a physical barrier, might influence IgG passage (Figure 1).13

Antinuclear antibody immune-complex deposition in lupus placenta

In lupus, autoantibody production against a wide variety of intracellular antigens reflects the autoantigen-mediated polyclonal activation of B cells. Antinuclear antibodies (ANAs) could form immune complexes (IC) in situ that are captured by the placenta during pregnancy, thereby preventing the transfer of maternal ANAs to the fetus. Thus, the placental tissue functions as an immunosorbent that traps ANA-ICs in the trophoblast and amnios.14 Subsequently, the ICs could activate the classic complement pathway; C3 and C1q fragments have been frequently observed in the trophoblast, suggesting decreased C3 and C4 lev-

---

**Figure 1.** Physiological and pathologic IgG transit through placenta. 1) Normally the maternal IgG may cross the placental barrier. 2) Placental IgG transcytosis occurs via Fc receptors (FcR). 3) Maternal IgG must cross the syncytiotrophoblast and reach the fetal vascular endothelium. 4) After FcR deliver its cargo, the receptor is recycled to form new IgG/FcR complexes. 5) SLE immune complexes (IC) can be trapped in placenta that function as an immunosorbent, IC trapping by FcγRIIa induces transduction signals that increase intracellular Ca2+, inositol-1,4,5-triphosphate, and phosphatidylinositol (IP4) levels, which promote the activation of IFN-γ and TNF, leading to vellitis and deciduitis.
els in maternal serum, in association with placent al dysfunction. In addition, IC trapping through FcR II/IIIa transduces signals that increase intracellular Ca\(^{2+}\), inositol-1,4,5-triphosphate, and phosphatidylinositol (IP\(_4\)) levels, promoting the activation of IFN-\(\gamma\) and TNF, which subsequently activate NK cells for antibody dependent cell mediated cytotoxicity (ADCC) cell mediated reactions leading to vellicitis and deciduitis, as commonly observed in the placentas of lupus patients (Figure 1).13,16,17

**Transplacental transit of maternal antinuclear antibodies**

In 1954, Bridge and Foley described the passive transfer of maternal ANA to the fetus. Indeed, these authors reported the placent al transfer of LE factor into newborns apparently without clinical consequences,16 and this finding has been confirmed by multiple reports.19-22 Nathan and Snapper were the first clinicians to describe a potential role for maternal lupus autoantibodies in neonates in a reported case of neonatal thrombocytopenia associated with maternal LE factor. These observations reflected a natural experiment induced by transplacental transit of maternal autoantibodies. Subsequently, different experimental approaches in rodents have been used to assess the placentary kinetics of ANA (anti-DNA, Sm, RNP, La, and anti-Ro), revealing that i) the entry of ANA into the fetus depends on the antibody concentration and FcR placental density; and ii) the transferred ANA is deposited into fetal tissues in a dose-dependent manner.23

**Neonatal pathology induced by maternal autoantibodies**

In 1954, McCuistion and Schoch described skin lesions in neonates associated with maternal ANA transfer. The authors reported the case of a newborn with discoid lupus whose mother had LE skin lesions, suggesting that the etiological agent was transmitted into the fetus through the placental pathway.24 However, this hypothesis was only proved 27 years later in 1981, when Thomas Provost et al. demonstrated that maternal anti-Ro antibodies caused neonatal lupus (NL), which was subsequently confirmed by William Weston et al.25-27 In 1977, Chameides contributed to the current understanding of the multiorganic spectrum of NL when he described congenital heart block (CHB) in newborns of mothers with SLE.

---

**Figure 2.** The pathologic mechanisms of CHB induced by maternal anti-Ro/La antibodies. Anti-Ro 52 bind fetal 5-HT4A because Ro52 possesses two sequences (residues 365-382 and 380-396) that share partial homology with the 5-HT4A serotonin receptor. This receptor is widely expressed in the atrial tissue of fetal heart. Maternal anti-Ro antibodies may therefore exert their pathogenetic activity by decoupling the excitation-contraction cycles of fetal heart, causing AV blockage of variable degree.
After observing fibrotic changes in the atrioventricular node during the autopsy of a newborn that died from CHB, this author suggested that these changes influenced this pathology, and the early development of this nodal fibrosis presumably contributed to the observed CHB. With or without the development of CHB, NL is a rare disease that typically depends on the expression of maternal anti-Ro/La antibodies. A few studies have reported anti-RNP specificity, but this association lacks experimental confirmation.

**Ro/SSA molecular complex**

Antibodies to Ro/SSA antigens are serological markers of Sjögren’s syndrome and some features of LE, such as subacute cutaneous lupus erythematosus (SCLE). Anti-Ro antibodies were discovered by Clark et al. and were then used as molecular probes to determine that the Ro complex includes the Ro60 ribonucleoprotein. Ro60 displays a donut-shaped form and associates with small cytoplasmic Y RNAs. Interestingly, Ro60, which is expressed in the nucleus and cytoplasm of lymphoid cells, also binds to RNAs that are incorrectly edited and cannot be translated. Ro60 has also been implicated in 5S rRNA editing and in the regulation of micro (mi) RNA biogenesis and RNA derivatives.

Ro52 is another component of the Ro complex. Interestingly, this ribonucleoprotein contains zinc finger domains and a leucine zipper; Ro52 is encoded by a different gene than Ro60 and contains zinc finger domains and a leucine zipper. Ro52 possesses two sequences at the periphery of the protein, referred to as owl eyes, and these babies might display polycyclic lesions mimicking those observed in SCLE. At the onset of or during exacerbation, the appearance of erythematous lesions is independent of photo exposure. Other less common skin lesions include petechiae, telangiectasia, and cutis marmorata.

The pathobiology of these neonate skin conditions shows lesions mimicking SCLE or neutrophilic dermatitis, accompanied by mononuclear cell infiltration into the perivascular and peridendral dermis and vacular degeneration of the basal cell layer.

Newborns exhibit periorbital erythema, which impedes the normal conduction of the electrical impulse to the ventricle. This pathology primarily affects the left ventricle and causes severe ventricular dysfunction. This fibroelastosis has not been definitively associated with AVB, and neonates with this condition may develop skin manifestations as early as 1 month after birth. Congenital structural abnormalities have also been associated with the presence of maternal autoantibodies, although this association is incidental rather than causative.

Experimental models for understanding the pathophysiology of CHB have been developed by different groups. The Buyon lab demonstrated toxic effects of maternal anti-Ro/La antibodies on the fetal cardiac conduction system. Using pregnant female Balb/c mice immunized with recombinant antigens, these researchers demonstrated that the offspring display CHB. Approximately 20% of the neonatal animals developed first-degree AVB after immunization with Ro60, and 7% of the neonatal animals developed first-degree AVB after immunization with the La/SSB antigen. Interestingly, animals immunized with the Ro52 alpha isoform developed Mobitz I AVB, while immunization with the beta isoform induced complete AVB. Clinical and experimental data have clearly demonstrated that anti-Ro antibodies induce CHB. However, because the Ro complex is intracellular, it was unclear how the maternal antibodies targeted the fetal intracellular anti-
gen. Using an in vitro system, Jill Buyon et al. demonstrated that Ro or La antigens were translocated to the cardiomyocyte cell surface through apoptotic membranes. Thus, the physiological programmed cell death observed during heart development favors the antigenic targeting of Ro/La antigens by maternal autoantibodies. Through this mechanism, autoantigens are externalized during apoptosis, and anti-Ro/La antibodies subsequently reach their target, releasing cytokines, such as TNF and TGF-β, that induce cardiomyocyte inflammation. In addition, TGF-β induces the trans-differentiation of cardiac fibroblasts, leading to fibrosis and AV node scarring, and stimulates the plasminogen activator receptor, which feeds the fibrotic process. The toxic effect of anti-Ro52 antibodies on the conduction system is dose-dependent. Studies have demonstrated that these antibodies alter cardiomyocyte calcium homeostasis. Notably, Ro52 epitopes derived from different epitopes may have significant morbidity and mortality, and the survival rate after 3 years is approximately 80%. When a child with CHB becomes an adult, their CHB history should be considered for managing associated comorbidities. Concerning maternal treatment during pregnancy, the administration of hydroxychloroquine together with a low dose of prednisone might exert protective effects. Other miscellaneous manifestations of NL include hepatobiliary damage, which can be associated with jaundice, cholestatic hepatitis, and occasional thrombocytopenia; anemia; hyperlipidemia; and elevated transaminase levels. The hepatic dysfunction occurs in utero or appears shortly after birth, and clinical and biochemical parameters typically return to normal after approximately eight weeks. Hemocytopenia has also been reported in 10% of NL cases, among which neutropenia and/or transitory lymphopenia are frequent. Other rare manifestations of NL occur in the central nervous system (CNS), including seizures, CNS bleeding, or myelopathy.

Conclusions

Lupus is a common disease in women of reproductive age. Thus, it is important to consider the possibility of neonatal syndromes induced through ANA maternal autoantibodies, including NL with or without CHB. As NL with CHB must be detected prenatally, adequate clinical, serological, and echocardiographic screening must be performed in all pregnant women with lupus or Sjögren's syndrome. After the pregnancy is resolved, systematic postnatal maternal tracking must be performed to determine the likelihood of NL in subsequent pregnancies. Moreover, this review acknowledges those who have performed studies on NL, particularly Tom Provost, who recently passed away. Indeed, his original contribution to these studies triggered a cascade of sophisticated research, revealing the cellular and molecular mechanisms underlying the pathogenic role of maternal anti-Ro/La antibodies in the induction of NL pathologies.

References


